Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivax Add-on to Standard Therapy in Glioblastoma Multiforme
NCT01213407Phase 2Completed
- Sponsor
- Activartis Biotech GmbH
- Start
- Apr 2010
- Primary completion
- Jun 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Trivax in glioblastoma multiforme (GBM) (2 arms), sponsored by Activartis Biotech GmbH. Primary endpoint: Progression Free Survival at 12 months. Started Apr 2010; status: completed.
02
Drugs
Trivax
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01213407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01213407.